EUCTR2017-002674-39-BE进行中（未招募）1 期
An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Must have completed the C3G Proof of Mechanism (POM) study
- •(ACH471-201) (participation in the long-term follow-up portion of
- •XML File Identifier: W7IWDxWydTWyK8OigMJAEawtqww=
- •ACH471-201 is not required) or must meet the following criteria:
- •a. Must have biopsy-confirmed primary C3G or IC-MPGN
- •b. Must have clinical evidence of ongoing disease based on significant proteinuria (defined as =500 mg/day of protein in a 24-hour urine)attributable to C3G disease or IC-MPGN in the opinion of the PI, and present prior to study entry and confirmed during Screening.
- •c. If a pre-treatment biopsy is obtained, or if a historical biopsy is
- •available for review, it must have no more than 50% global fibrosis and no more than 50% of glomeruli with cellular crescents
- •d. Must be 12 years or age or older and capable of swallowing tablets
- •2. If on corticosteroids, anti-hypertensive medications, anti-proteinuric medications (e.g., ACE inhibitors or angiotensin receptor blockers [ARBs]), or mycophenolate mofetil (MMF), must be on a stable dose for at least 2 weeks prior to screening
- •3. Female participants of childbearing potential must agree to use an
- •acceptable method of contraception (as defined in Section 5.5.5) from the date of signing the informed consent to the first day of dosing (Day 1), and must agree to use a highly effective form of contraception (as defined in Section 5.5.5) from the first day of dosing to 30 days after their last dose of study drug. Female participants of childbearing potential must also have a negative serum pregnancy test during Screening and negative urine pregnancy test on Day 1. Female participants of non-childbearing potential need not employ a method of contraception.
- •4. Non-sterile male participants must agree to use a highly effective
- •form of contraception (as defined in Section 5.5.5) with their partner(s) of childbearing potential from the first day of dosing to 90 days after their last dose of study drug. Male participants who are surgically sterile need not employ additional contraception. Male participants must agree not to donate sperm while enrolled in this study and for up to 90 days after their last dose of study drug.
- •5. Adult participants must be capable of providing written informed
- •consent, and adolescent participants must be capable of providing
- •written assent. All participants must be willing and able to comply with the requirements and restrictions listed in the consent form and with all procedures in the protocol, including, the visit schedule, the treatment plan, the schedule for laboratory testing, and other study procedures
- •6. Must be up-to-date on routine vaccinations, or willing to be brought up-to-date, based on local guidelines
- •7. Must have access to emergency medical care
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 3
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 19
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Have a history of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant
- •2. Have a history or presence of any clinically relevant co-morbidities
- •that would make the participant inappropriate for the study (for
- •example, a comorbidity which is likely to result in deterioration of the
- •participant's condition, affect the participant's safety during the study, or confound the results of the study), in the opinion of the PI
- •3. Have an estimated GFR <30 mL/min/1.73 m2 at the time of screening or at any time over the preceding four weeks
- •4. Is a renal transplant recipient or receiving renal replacement therapy
- •5. Have other renal diseases that would interfere with interpretation of the study
- •6. Have evidence of monoclonal gammopathy of unclear
- •significance(MGUS), infections, malignancy, autoimmune diseases, or
- •other conditions to which C3G or IC-MPGN is secondary
- •7. Have been diagnosed with or show evidence of hepatobiliary
- •cholestasis
- •8. Females who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of ACH-0144471 administration or participants with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days of ACH-0144471 administration
- •9. Have a history of febrile illness, a body temperature >38°C, or other evidence of a clinically significant active infection, within 14 days prior to ACH-0144471 administration
- •10. Have evidence of human immunodeficiency virus (HIV), hepatitis B infection, or active hepatitis C infection at Screening
- •11. Have a history of meningococcal infection within the prior year
- •12. Have a history of hypersensitivity reactions to commonly used
- •antibacterial agents, including beta-lactams, penicillin, aminopenicillins, fluoroquinolones, cephalosporins, and carbapenems, which, in the opinion of the investigator and/or an appropriately qualified immunology or infectious disease expert, would make it difficult to properly provide either empiric antibiotic therapy or treat an active infection.
- •13. Have participated in a clinical study in which an investigational drug was given within 30 days, or within 5 half-lives of the investigational drug, whichever is longer, prior to the first dose of ACH-0144471
- •14. Have received eculizumab at any dose or interval within the past 50 days prior to the first dose of ACH-0144471
- •15. Have received tacrolimus or cyclosporine within 2 weeks of the first dose of ACH-0144471
- •16. Have a 12-lead ECG with a QTcF >450 msec for males or >470 msec for females, or have ECG findings which, in the opinion of the PI, could put the participant at undue risk
- •17. Have received any drug known to prolong the QTc interval within 2 weeks of the first dose of ACH-0144471 and which, in the opinion of the PI, could put the participant at undue risk
- •18. Have any of the following laboratory abnormalities at screening:
- •Alanine transaminase (ALT) > upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) > ULN
- •Absolute neutrophil counts (ANC) <1,000/µL
- •Total bilirubin >1.5× ULN
- •Indirect bilirubin > ULN
- •Any laboratory abnormality that, in the opinion of the PI, would
- •make the particpant inappropriate for the study
- •19. Are unwilling or unable to comply with the study protocol for any
研究者
相似试验
进行中（未招募）
1 期
A treatment study of ACH-0144471 in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)EUCTR2017-002674-39-NLAchillion Pharmaceuticals, Inc.20
进行中（未招募）
1 期
A treatment study of ACH-0144471 in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (ICMPGN)EUCTR2017-002674-39-ITACHILLION PHARMACEUTICALS, INC.20
已完成
2 期
An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471.kidney diseaseDense Deposit DiseaseNL-OMON50417Achillion Pharmaceuticals3
进行中（未招募）
1 期
A clinical study to investigate the effectiveness and safety of treatment with the drug APD334 in ulcerative colitis and crohn's disease patients with skin conditionsActive Skin Extra-Intestinal Manifestations in Inflammatory Bowel Disease.EUCTR2016-003797-40-DEArena Pharmaceuticals, Inc.20
进行中（未招募）
1 期
A clinical study to investigate the effectiveness and safety of treatment with the drug APD334 in ulcerative colitis and crohn's disease patients with skin conditionsEUCTR2016-003797-40-BEArena Pharmaceuticals, Inc.20